CoChat
Sign Up
Cited by 113Genetics and Neurodevelopmental DisordersChromatin Remodeling and CancerGenomic variations and chromosomal abnormalities

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Arid1b haploinsufficient mice reveal neuropsychiatric phenotypes and reversible causes of growth impairment

Open access
Celen, Cemre, Chuang, Jen-Chieh, Luo, Xin, Nijem, Nadine, Walker, Angela K, Chen, Fei, Zhang, Shuyuan, Chung, Andrew S, Nguyen, Liem H, Nassour, Ibrahim, Budhipramono, Albert, Sun, Xuxu, Bok, Levinus A, McEntagart, Meriel, Gevers, Evelien F, Birnbaum, Shari G, Eisch, Amelia J, Powell, Craig M, Ge, Woo-Ping, Santen, Gijs WE, Chahrour, Maria, Zhu, Hao·2017·eLife
DOI 10.7554/elife.25730PMC PMC5515576
Open this paper in CoChat — free account

Abstract

Sequencing studies have implicated haploinsufficiency of ARID1B , a SWI/SNF chromatin-remodeling subunit, in short stature (Yu et al., 2015), autism spectrum disorder (O'Roak et al., 2012), intellectual disability (Deciphering Developmental Disorders Study, 2015), and corpus callosum agenesis (Halgren et al., 2012). In addition, ARID1B is the most common cause of Coffin-Siris syndrome, a developmental delay syndrome characterized by some of the above abnormalities (Santen et al., 2012; Tsurusaki et al., 2012; Wieczorek et al., 2013). We generated Arid1b heterozygous mice, which showed social behavior impairment, altered vocalization, anxiety-like behavior, neuroanatomical abnormalities, and growth impairment. In the brain, Arid1b haploinsufficiency resulted in changes in the expression of SWI/SNF-regulated genes implicated in neuropsychiatric disorders. A focus on reversible mechanisms identified Insulin-like growth factor (IGF1) deficiency with inadequate compensation by Growth hormone-releasing hormone (GHRH) and Growth hormone (GH), underappreciated findings in ARID1B patients. Therapeutically, GH supplementation was able to correct growth retardation and muscle weakness. This model functionally validates the involvement of ARID1B in human disorders, and allows mechanistic dissection of neurodevelopmental diseases linked to chromatin-remodeling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.25730

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Arid1b+/- mice exhibit physical manifestations of developmental delay, autistic-like features, and abnormal behavioral phenotypes. (A) Schematic of Arid1b whole body heterozygous mice in which exon five is deleted (hereafter referred as Arid1b+/-) and Arid1b floxed mice. (B) Relative Arid1b mRNA levels in selected organs and brain regions as assessed by qPCR. (C) Relative Arid1b levels in p0 mouse limb (top panel) and whole brain extracts at p45 as assessed by western blot analysis. (D) Appearance of WT and Arid1b+/- mice at postnatal day 0. (E) Appearance of WT and Arid1b+/- littermates at 1 month of age. (F) Juvenile social interaction testing for 10 WT and 9 Arid1b+/- male mice. (G) Grooming test for 10 WT and 9 Arid1b+/- female mice. (H, I) The ultrasonic vocalization (USV) test measuring the duration and frequency of vocal communication in 63 WT and 33 Arid1b+/- male and female mice during separation of pups from dams at postnatal day 4. (J) Representative traces of WT and Arid1b+/- mice in the open field and time spent in the indicated areas for 20 WT and 20 Arid1b+/- 8 week old male mice. (K) Representative traces of WT and Arid1b+/- mice in the elevated plus maze and time spent in the indicated areas for 20 WT and 20 Arid1b+/- 8 week old male mice. (L) Dark-light box testing for 20 WT and 20 Arid1b+/- 8 week old male mice. Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes, *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.003
Figure 1. Arid1b+/- mice exhibit physical manifestations of developmental delay, autistic-like features, and abnormal behavioral phenotypes. (A) Schematic of Arid1b whole body heterozygous mice in which exon five is deleted (hereafter referred as Arid1b+/-) and Arid1b floxed mice. (B) Relative Arid1b mRNA levels in selected organs and brain regions as assessed by qPCR. (C) Relative Arid1b levels in p0 mouse limb (top panel) and whole brain extracts at p45 as assessed by western blot analysis. (D) Appearance of WT and Arid1b+/- mice at postnatal day 0. (E) Appearance of WT and Arid1b+/- littermates at 1 month of age. (F) Juvenile social interaction testing for 10 WT and 9 Arid1b+/- male mice. (G) Grooming test for 10 WT and 9 Arid1b+/- female mice. (H, I) The ultrasonic vocalization (USV) test measuring the duration and frequency of vocal communication in 63 WT and 33 Arid1b+/- male and female mice during separation of pups from dams at postnatal day 4. (J) Representative traces of WT and Arid1b+/- mice in the open field and time spent in the indicated areas for 20 WT and 20 Arid1b+/- 8 week old male mice. (K) Representative traces of WT and Arid1b+/- mice in the elevated plus maze and time spent in the indicated areas for 20 WT and 20 Arid1b+/- 8 week old male mice. (L) Dark-light box testing for 20 WT and 20 Arid1b+/- 8 week old male mice. Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes, *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.003CC BY · PubMed Central
Figure 1—figure supplement 1. Additional characterization of Arid1b+/- mice. (A) Arid1b in situ hybridization showing a sagittal brain section from an 8 week old male mouse. Hippocampus and cerebellum showed high levels of signal. Image taken from the Allen Brain Atlas. (B) Serum electrolytes including potassium (K+), creatinine (CREA), and blood urea nitrogen (BUN) measured in 100 day-old females (n = 9 WT and 9 Arid1b+/-). (C) Liver function tests including Aspartate transaminase (AST), Alanine amino transferase (ALT), and Albumin (ALB) in 100 day old females (n = 9 WT and 10 Arid1b+/-). (D) Blood cell counts including white blood cells (WBC), red blood cells (RBC), and platelets (PLT) measured in 100 day old females (n = 9 WT and 10 Arid1b+/-). (E) 0/389 WT and 16/272 (6.6%) Arid1b+/- mice had grossly appreciable hydrocephalus. Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes: *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.005
Figure 1—figure supplement 1. Additional characterization of Arid1b+/- mice. (A) Arid1b in situ hybridization showing a sagittal brain section from an 8 week old male mouse. Hippocampus and cerebellum showed high levels of signal. Image taken from the Allen Brain Atlas. (B) Serum electrolytes including potassium (K+), creatinine (CREA), and blood urea nitrogen (BUN) measured in 100 day-old females (n = 9 WT and 9 Arid1b+/-). (C) Liver function tests including Aspartate transaminase (AST), Alanine amino transferase (ALT), and Albumin (ALB) in 100 day old females (n = 9 WT and 10 Arid1b+/-). (D) Blood cell counts including white blood cells (WBC), red blood cells (RBC), and platelets (PLT) measured in 100 day old females (n = 9 WT and 10 Arid1b+/-). (E) 0/389 WT and 16/272 (6.6%) Arid1b+/- mice had grossly appreciable hydrocephalus. Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes: *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.005CC BY · PubMed Central
Figure 1—figure supplement 2. Additional neurobehavioral testing on Arid1b+/- mice. (A) Marble burying test for 10 WT and 9 Arid1b+/- female mice. (B) Representative spectrograms of WT and Arid1b+/- vocalizations. (C) Number of vocalization calls of 63 WT and 33 Arid1b+/- male and female mice. (D) Locomotor activity quantified by number of beam breaks in a familiar home-cage environment within periodic time intervals over the course of two hours. Two-way repeated measures ANOVA was used to calculate the p-value (left). Total number of beam breaks during two hours, analyzed with Student’s t-test (right). 8 week old male mice (n = 20 WT and 20 Arid1b+/-) were used. (E) Time spent in the target quadrant vs. other quadrants in the probe testing of the water maze test at day 14. The target quadrant contains a hidden platform. 20 WT and 20 Arid1b+/- mice were examined (left). Number of target quadrant crossings in the probe testing of the water maze test at day 14 (right). 20 WT and 20 Arid1b+/- mice were examined. (F) Percent freezing time was quantified in the contextual fear conditioning test (n = 10 WT and 11 Arid1b+/- 8 week old male mice). (G) Percent freezing time was quantified in the cued fear conditioning test (n = 10 WT and 11 Arid1b+/- 8 week old male mice). (H) Foot shock sensitivity testing (n = 10 WT and 11 Arid1b+/- 8 week old male mice). Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes: *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the corresponding figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.007
Figure 1—figure supplement 2. Additional neurobehavioral testing on Arid1b+/- mice. (A) Marble burying test for 10 WT and 9 Arid1b+/- female mice. (B) Representative spectrograms of WT and Arid1b+/- vocalizations. (C) Number of vocalization calls of 63 WT and 33 Arid1b+/- male and female mice. (D) Locomotor activity quantified by number of beam breaks in a familiar home-cage environment within periodic time intervals over the course of two hours. Two-way repeated measures ANOVA was used to calculate the p-value (left). Total number of beam breaks during two hours, analyzed with Student’s t-test (right). 8 week old male mice (n = 20 WT and 20 Arid1b+/-) were used. (E) Time spent in the target quadrant vs. other quadrants in the probe testing of the water maze test at day 14. The target quadrant contains a hidden platform. 20 WT and 20 Arid1b+/- mice were examined (left). Number of target quadrant crossings in the probe testing of the water maze test at day 14 (right). 20 WT and 20 Arid1b+/- mice were examined. (F) Percent freezing time was quantified in the contextual fear conditioning test (n = 10 WT and 11 Arid1b+/- 8 week old male mice). (G) Percent freezing time was quantified in the cued fear conditioning test (n = 10 WT and 11 Arid1b+/- 8 week old male mice). (H) Foot shock sensitivity testing (n = 10 WT and 11 Arid1b+/- 8 week old male mice). Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes: *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the corresponding figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.007CC BY · PubMed Central
Figure 2. Arid1b haploinsufficiency results in neuroanatomical abnormalities implicated in neuropsychiatric diseases. (A) Relative corpus callosum volume quantified through Cavalieri analysis (n = 8 WT and 7 Arid1b+/- brains from 50 day old females). (B) Dentate gyrus volume quantified through Cavalieri analysis (n = 7 WT and 7 Arid1b+/- brains from 50 day old females). (C) Representative Ki67 immunostaining. (D) Quantitation of Ki67+ total cell number (8 WT and 7 Arid1b+/- brains from 50 day old females). (E) Bregma analysis was used to determine cell proliferation (Ki67) as a function of location in the subgranular zone of the dentate gyrus. Two-way ANOVA with uncorrected Fischer’s Least Significant Difference (LSD) was used to calculate the statistics. (F) Representative BrdU immunostaining. WT and Arid1b+/- mice received one injection per day of the thymidine analog, bromodeoxyuridine (BrdU), for five days and brains were harvested three days following the last injection (6 WT and 4 Arid1b+/- brains from 50 day old females). (G) Quantification of BrdU+ total cell number. (H) Bregma analysis was used to determine cell proliferation (BrdU) as a function of location in the subgranular zone of the dentate gyrus (n = 6 WT and 4 Arid1b+/-). Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes, *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.009
Figure 2. Arid1b haploinsufficiency results in neuroanatomical abnormalities implicated in neuropsychiatric diseases. (A) Relative corpus callosum volume quantified through Cavalieri analysis (n = 8 WT and 7 Arid1b+/- brains from 50 day old females). (B) Dentate gyrus volume quantified through Cavalieri analysis (n = 7 WT and 7 Arid1b+/- brains from 50 day old females). (C) Representative Ki67 immunostaining. (D) Quantitation of Ki67+ total cell number (8 WT and 7 Arid1b+/- brains from 50 day old females). (E) Bregma analysis was used to determine cell proliferation (Ki67) as a function of location in the subgranular zone of the dentate gyrus. Two-way ANOVA with uncorrected Fischer’s Least Significant Difference (LSD) was used to calculate the statistics. (F) Representative BrdU immunostaining. WT and Arid1b+/- mice received one injection per day of the thymidine analog, bromodeoxyuridine (BrdU), for five days and brains were harvested three days following the last injection (6 WT and 4 Arid1b+/- brains from 50 day old females). (G) Quantification of BrdU+ total cell number. (H) Bregma analysis was used to determine cell proliferation (BrdU) as a function of location in the subgranular zone of the dentate gyrus (n = 6 WT and 4 Arid1b+/-). Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes, *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.009CC BY · PubMed Central
Figure 2—figure supplement 1. Arid1b+/- and Arid1b-/- brains have defects in cortical development. (A) Hoechst staining of WT, Arid1b+/-, and Arid1b-/- brain sections showing cortical thickness differences outlined by the region in the white box. (B) Quantification of cortical thickness in WT, Arid1b+/-, and Arid1b-/- brain sections (the n is at the bottom of each bar). (C) Close up view of cortical regions in the white box from (A) above, showing reduced cortical thickness and cellularity. (D) TBR1 staining in WT and Arid1b-/- cortex showing neuron numbers. DOI: http://dx.doi.org/10.7554/eLife.25730.011
Figure 2—figure supplement 1. Arid1b+/- and Arid1b-/- brains have defects in cortical development. (A) Hoechst staining of WT, Arid1b+/-, and Arid1b-/- brain sections showing cortical thickness differences outlined by the region in the white box. (B) Quantification of cortical thickness in WT, Arid1b+/-, and Arid1b-/- brain sections (the n is at the bottom of each bar). (C) Close up view of cortical regions in the white box from (A) above, showing reduced cortical thickness and cellularity. (D) TBR1 staining in WT and Arid1b-/- cortex showing neuron numbers. DOI: http://dx.doi.org/10.7554/eLife.25730.011CC BY · PubMed Central
Figure 3. Arid1b haploinsufficiency results in changes in the expression of SWI/SNF regulated genes implicated in neuropsychiatric diseases. (A) All significantly up- and downregulated genes in the Arid1b+/- hippocampus are ranked according to p-value (least to most significant from left to right). (B) Most enriched diseases and biological functions in hippocampus. (C) Most differentially regulated pathways in the hippocampus. (D) 14 of 140 (10%) differentially regulated genes were among the highest ranking autism risk genes identified in the SFARI database. Category S: syndromic, Category 1: high confidence, Category 2: strong candidate, Category 3: suggestive evidence, Category 4: minimal evidence, Category 5: Hypothesized (Basu et al., 2009). (E) Pie chart showing that 91 of 140 (65%) differentially regulated genes in hippocampus are direct targets of Brg1, a core SWI/SNF complex subunit. Brg1 target genes were identified using ChIP-Seq in mouse e11.5 forebrain (Attanasio et al., 2014). (F) Metaplot showing enrichment of Brg1 at the TSSs of genes regulated by Arid1b. (G) Heatmap showing Brg1 promoter binding in these genes. (H) Differential mRNA expression of representative genes involved in neurodevelopment and ASD (Data from: SFARI database, updated September, 2016) (Basu et al., 2009). (I) Brg1 peaks suggesting direct binding of SWI/SNF at the promoters of ASD-related genes. Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes, *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the corresponding figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.013
Figure 3. Arid1b haploinsufficiency results in changes in the expression of SWI/SNF regulated genes implicated in neuropsychiatric diseases. (A) All significantly up- and downregulated genes in the Arid1b+/- hippocampus are ranked according to p-value (least to most significant from left to right). (B) Most enriched diseases and biological functions in hippocampus. (C) Most differentially regulated pathways in the hippocampus. (D) 14 of 140 (10%) differentially regulated genes were among the highest ranking autism risk genes identified in the SFARI database. Category S: syndromic, Category 1: high confidence, Category 2: strong candidate, Category 3: suggestive evidence, Category 4: minimal evidence, Category 5: Hypothesized (Basu et al., 2009). (E) Pie chart showing that 91 of 140 (65%) differentially regulated genes in hippocampus are direct targets of Brg1, a core SWI/SNF complex subunit. Brg1 target genes were identified using ChIP-Seq in mouse e11.5 forebrain (Attanasio et al., 2014). (F) Metaplot showing enrichment of Brg1 at the TSSs of genes regulated by Arid1b. (G) Heatmap showing Brg1 promoter binding in these genes. (H) Differential mRNA expression of representative genes involved in neurodevelopment and ASD (Data from: SFARI database, updated September, 2016) (Basu et al., 2009). (I) Brg1 peaks suggesting direct binding of SWI/SNF at the promoters of ASD-related genes. Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes, *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the corresponding figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.013CC BY · PubMed Central
Figure 4. Growth retardation in Arid1b+/- mice is due to GH-IGF1 axis deficiency with a neuronal source. (A) Body length (nose-to-rump) curve of females (n = 9 WT and 9 Arid1b+/-). (B) Body weight growth curve for males (n = 14 WT and 14 Arid1b+/-) and females (n = 20 WT and 20 Arid1b+/-). For (A) and (B), repeated ANOVA with Bonferroni’s post-hoc analysis was used. (C) Plasma IGF1 as measured by ELISA (n = 16 WT and 19 Arid1b+/- 28–41 day old male and female mice). (D) Igf1 mRNA in WT and Arid1b+/- livers as measured by qPCR (n = 5 WT and 5 Arid1b+/- livers from 45 day old female mice). (E) Plasma GH as measured by ELISA (n = 15 WT and 14 Arid1b+/- 28–41 day old male and female mice). (F) Gh mRNA in WT and Arid1b+/- pituitary as measured by qPCR (n = 6 WT and 5 Arid1b+/- pituitary from 33-44 day old female mice). (G) Plasma GH (n = 9 WT and 9 Arid1b+/- 2 week old male mice). (H) Plasma GH before and after stimulation by human GHRH (n = 19 WT and n = 20 Arid1b+/- mice at baseline, n = 11 WT and n = 10 Arid1b+/- mice 5 and 15 min after GHRH administration). (I) Ghrh mRNA in WT and Arid1b+/- mediobasal hypothalamus as measured by qPCR. (n = 8 WT and 7 Arid1b+/- samples from 33-44 day old female mice). (J) Body weight curve for female Arid1bFl/+ (n = 9) and Albumin-Cre; Arid1bFl/+ (n = 15) mice. (K) Body weight curve for female Arid1bFl/+ (n = 10) and Nestin-Cre; Arid1bFl/+ (n = 6) mice. (L) Plasma IGF1 levels for 40–45 day old female Arid1bFl/+ (n = 7) and Albumin-Cre; Arid1bFl/+ (n = 7) mice. (M) Plasma IGF1 levels for 30–45 days old female Arid1bFl/+ (n = 6) and Nestin-Cre; Arid1bFl/+ (n = 6) mice. (N) Plasma GH levels for female Arid1bFl/+ (n = 5) and Nestin-Cre; Arid1bFl/+ (n = 5) mice. Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes, *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.014
Figure 4. Growth retardation in Arid1b+/- mice is due to GH-IGF1 axis deficiency with a neuronal source. (A) Body length (nose-to-rump) curve of females (n = 9 WT and 9 Arid1b+/-). (B) Body weight growth curve for males (n = 14 WT and 14 Arid1b+/-) and females (n = 20 WT and 20 Arid1b+/-). For (A) and (B), repeated ANOVA with Bonferroni’s post-hoc analysis was used. (C) Plasma IGF1 as measured by ELISA (n = 16 WT and 19 Arid1b+/- 28–41 day old male and female mice). (D) Igf1 mRNA in WT and Arid1b+/- livers as measured by qPCR (n = 5 WT and 5 Arid1b+/- livers from 45 day old female mice). (E) Plasma GH as measured by ELISA (n = 15 WT and 14 Arid1b+/- 28–41 day old male and female mice). (F) Gh mRNA in WT and Arid1b+/- pituitary as measured by qPCR (n = 6 WT and 5 Arid1b+/- pituitary from 33-44 day old female mice). (G) Plasma GH (n = 9 WT and 9 Arid1b+/- 2 week old male mice). (H) Plasma GH before and after stimulation by human GHRH (n = 19 WT and n = 20 Arid1b+/- mice at baseline, n = 11 WT and n = 10 Arid1b+/- mice 5 and 15 min after GHRH administration). (I) Ghrh mRNA in WT and Arid1b+/- mediobasal hypothalamus as measured by qPCR. (n = 8 WT and 7 Arid1b+/- samples from 33-44 day old female mice). (J) Body weight curve for female Arid1bFl/+ (n = 9) and Albumin-Cre; Arid1bFl/+ (n = 15) mice. (K) Body weight curve for female Arid1bFl/+ (n = 10) and Nestin-Cre; Arid1bFl/+ (n = 6) mice. (L) Plasma IGF1 levels for 40–45 day old female Arid1bFl/+ (n = 7) and Albumin-Cre; Arid1bFl/+ (n = 7) mice. (M) Plasma IGF1 levels for 30–45 days old female Arid1bFl/+ (n = 6) and Nestin-Cre; Arid1bFl/+ (n = 6) mice. (N) Plasma GH levels for female Arid1bFl/+ (n = 5) and Nestin-Cre; Arid1bFl/+ (n = 5) mice. Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes, *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.014CC BY · PubMed Central
Figure 4—figure supplement 1. Growth and metabolic analysis of Arid1b+/- mice. (A) Arid1b+/- organ/body weight ratios presented as % of WT organ/body weight ratio. (B) Food intake and(C) water consumption was quantified in a metabolic cage over 4 days. The absolute data was normalized to body weight (n = 12 WT and 12 Arid1b+/-8 week old male mice). Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes: *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.016
Figure 4—figure supplement 1. Growth and metabolic analysis of Arid1b+/- mice. (A) Arid1b+/- organ/body weight ratios presented as % of WT organ/body weight ratio. (B) Food intake and(C) water consumption was quantified in a metabolic cage over 4 days. The absolute data was normalized to body weight (n = 12 WT and 12 Arid1b+/-8 week old male mice). Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes: *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the figure legend. DOI: http://dx.doi.org/10.7554/eLife.25730.016CC BY · PubMed Central
Figure 5. GH therapy reverses growth retardation and muscle weakness. (A) Body weights at p50 (WT + vehicle (n = 12), WT + rhIGF1 (n = 12), Arid1b+/- + vehicle (n = 13) and Arid1b+/- + rhIGF1 (n = 13)). (B) Time spent in the closed arms of elevated plus maze at p50 (WT + vehicle (n = 27), WT + rhIGF1 (n = 29), Arid1b+/- + vehicle (n = 21) and Arid1b+/- + rhIGF1 (n = 22)). For (A) and (B), 0.5 mg/kg rhIGF1 was administrated daily starting from postnatal day 11. (C) Schema showing the duration and dose of daily recombinant GH treatment. (D) Body weights at p50 (WT + vehicle (n = 20), WT + rmGH (n = 16), Arid1b+/- + vehicle (n = 16) and Arid1b+/- + rmGH (n = 16)). (E) Nose-to-rump lengths at p50 (WT + vehicle (n = 7), WT + rmGH (n = 7), Arid1b+/- + vehicle (n = 6) and Arid1b+/- + rmGH (n = 6)). (F) Forelimb grip strength at p50 (WT + vehicle (n = 9), WT + rmGH (n = 9), Arid1b+/- + vehicle (n = 9) and Arid1b+/- + rmGH (n = 9)). (G) Hindlimb grip strength at p50 (WT + vehicle (n = 9), WT + rmGH (n = 9), Arid1b+/- + vehicle (n = 9) and Arid1b+/- + rmGH (n = 9)). (H) Time spent in the closed arms of elevated plus maze at p50 (WT + vehicle (n = 19), WT + rmGH (n = 16), Arid1b+/- + vehicle (n = 19) and Arid1b+/- + rmGH (n = 16)). Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes: *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Two-way ANOVA was used to calculate the p-value. DOI: http://dx.doi.org/10.7554/eLife.25730.018
Figure 5. GH therapy reverses growth retardation and muscle weakness. (A) Body weights at p50 (WT + vehicle (n = 12), WT + rhIGF1 (n = 12), Arid1b+/- + vehicle (n = 13) and Arid1b+/- + rhIGF1 (n = 13)). (B) Time spent in the closed arms of elevated plus maze at p50 (WT + vehicle (n = 27), WT + rhIGF1 (n = 29), Arid1b+/- + vehicle (n = 21) and Arid1b+/- + rhIGF1 (n = 22)). For (A) and (B), 0.5 mg/kg rhIGF1 was administrated daily starting from postnatal day 11. (C) Schema showing the duration and dose of daily recombinant GH treatment. (D) Body weights at p50 (WT + vehicle (n = 20), WT + rmGH (n = 16), Arid1b+/- + vehicle (n = 16) and Arid1b+/- + rmGH (n = 16)). (E) Nose-to-rump lengths at p50 (WT + vehicle (n = 7), WT + rmGH (n = 7), Arid1b+/- + vehicle (n = 6) and Arid1b+/- + rmGH (n = 6)). (F) Forelimb grip strength at p50 (WT + vehicle (n = 9), WT + rmGH (n = 9), Arid1b+/- + vehicle (n = 9) and Arid1b+/- + rmGH (n = 9)). (G) Hindlimb grip strength at p50 (WT + vehicle (n = 9), WT + rmGH (n = 9), Arid1b+/- + vehicle (n = 9) and Arid1b+/- + rmGH (n = 9)). (H) Time spent in the closed arms of elevated plus maze at p50 (WT + vehicle (n = 19), WT + rmGH (n = 16), Arid1b+/- + vehicle (n = 19) and Arid1b+/- + rmGH (n = 16)). Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes: *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001; ns, not significant. Two-way ANOVA was used to calculate the p-value. DOI: http://dx.doi.org/10.7554/eLife.25730.018CC BY · PubMed Central
Figure 5—figure supplement 1. Two ARID1B mutant CSS patients were GH deficient and responsive to GH replacement. (A) Growth curve of a CSS patient with an ARID1B mutation. GH treatments started at 2 years of age. Green shaded area represents the normal range. (B) Growth curve of a CSS patient with a 6q21.5 deletion, which includes the ARID1B locus. GH treatments started at 5.5 years of age. DOI: http://dx.doi.org/10.7554/eLife.25730.020
Figure 5—figure supplement 1. Two ARID1B mutant CSS patients were GH deficient and responsive to GH replacement. (A) Growth curve of a CSS patient with an ARID1B mutation. GH treatments started at 2 years of age. Green shaded area represents the normal range. (B) Growth curve of a CSS patient with a 6q21.5 deletion, which includes the ARID1B locus. GH treatments started at 5.5 years of age. DOI: http://dx.doi.org/10.7554/eLife.25730.020CC BY · PubMed Central
Author response image 1. DOI: http://dx.doi.org/10.7554/eLife.25730.022
Author response image 1. DOI: http://dx.doi.org/10.7554/eLife.25730.022CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

Sorted by citations

See all 113

Related

Metadata

Authors
Celen, C., Chuang, J.-C., Luo, X., Nijem, N., Walker, A. K., Chen, F., Zhang, S., Chung, A. S., Nguyen, L. H., Nassour, I., Budhipramono, A., Sun, X., Bok, L. A., McEntagart, M., Gevers, E. F., Birnbaum, S. G., Eisch, A. J., Powell, C. M., Ge, W.-P., Santen, G. W., Chahrour, M., & Zhu, H.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Máxima Medisch Centrum (NL)
  • Great Ormond Street Hospital (GB)
  • Queen Mary University of London (GB)
  • Children's Hospital of Philadelphia (US)
  • Leiden University Medical Center (NL)
Corresponding author
Zhu, Hao
ORCID
Venue
eLife
Publisher
eLife Sciences Publications, Ltd
Published
2017-07-11
Volume
6
ISSN
2050-084X (ISSN-L)
DOI
10.7554/elife.25730
PMC
PMC5515576
OpenAlex
W2734654523
Cited by
113
References
43
Citations by year
2026: 7 · 2025: 5 · 2024: 18 · 2023: 11 · 2022: 14 · 2021: 19 · 2020: 22 · 2019: 8 · 2018: 6 · 2017: 2
FWCI
6.88
Type
journal article
Language
en
Open access
Licence
Locations
  • eLife (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • St George's Online Research Archive (St George's University of London) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Hamon Center for Regenerative Science and Medicine (Regenerative medicine training grant)
  • Postdoctoral Institutional training grant (NIDA T32-DA007290)
  • HHMI International Student Research Fellowship
  • National Institutes of Health (DA023701, DA023555, MH107945, R21(NS099950), 1K08CA157727)
  • National Institute of Neurological Disorders and Stroke (NINDS K99/R00 (R00NS073735))
  • Pollock Foundation
  • National Cancer Institute (1R01CA190525)
  • Burroughs Wellcome Fund
  • CPRIT New Investigator Award (R1209)
  • CPRIT Early Translation Grant (DP150077)
  • University of Texas Southwestern Medical Center
  • NARSAD Young Investigator Grant (NARSAD 24951)
  • Cancer Prevention and Research Institute of Texas (RP150596)
  • Barts Health NHS Trust
  • Queen Mary University London
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
Keywords
ARID1B, haploinsufficiency, SWI/SNF chromatin remodeling, growth retardation, short stature, Coffin-Siris syndrome, autism spectrum disorder, intellectual disability, social behavior impairment, anxiety-like behavior, vocalizations, neuroanatomical abnormalities, growth hormone, growth hormone-releasing hormone, growth hormone supplementation, neuropsychiatric disorders, muscle weakness
MeSH terms
Animals, Behavior, Animal, Mental Disorders, Brain, Developmental Disabilities, Disease Models, Animal, Gene Expression Regulation, Heterozygote, Insulin-Like Growth Factor I, Growth Hormone-Releasing Hormone, Transcription Factors, Protein Serine-Threonine Kinases, Mice, Haploinsufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review